$44.03
Bristol-Myers Squibb Co is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.
Insights on Bristol-myers Squibb Co.
Revenue is up for the last 3 quarters, 10.96B → 11.86B (in $), with an average increase of 3.9% per quarter
Netprofit is down for the last 5 quarters, 2.26B → -11.91B (in $), with an average decrease of 200.0% per quarter
In the last 1 year, Eli Lilly And Company has given 74.1% return, outperforming this stock by 107.2%
In the last 3 years, Eli Lilly And Company has given 291.8% return, outperforming this stock by 324.6%
0.67%
Downside
Day's Volatility :1.09%
Upside
0.42%
1.59%
Downside
52 Weeks Volatility :32.71%
Upside
31.62%
Period | Bristol-myers Squibb Co. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -11.69% | 0.5% | 5.9% |
6 Months | -9.96% | 14.1% | 17.5% |
1 Year | -33.13% | 11.4% | 26.5% |
3 Years | -32.83% | 18.9% | 28.9% |
Market Capitalization | 89.3B |
Book Value | $8.14 |
Dividend Share | 2.34 |
Dividend Yield | 5.44% |
Earnings Per Share (EPS) | -3.1 |
PEG Ratio | 2.24 |
Wall Street Target Price | 53.3 |
Profit Margin | -13.5% |
Operating Margin TTM | 19.25% |
Return On Assets TTM | 5.39% |
Return On Equity TTM | -25.33% |
Revenue TTM | 45.5B |
Revenue Per Share TTM | 22.21 |
Quarterly Revenue Growth YOY | 4.7% |
Gross Profit TTM | 36.4B |
EBITDA | 18.2B |
Diluted Eps TTM | -3.1 |
Quarterly Earnings Growth YOY | -0.09 |
EPS Estimate Current Year | 0.56 |
EPS Estimate Next Year | 6.92 |
EPS Estimate Current Quarter | -4.44 |
EPS Estimate Next Quarter | 1.75 |
What analysts predicted
Upside of 21.05%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 22.6B | ↑ 8.59% |
Net Income | 5.0B | ↑ 391.76% |
Net Profit Margin | 21.95% | ↑ 17.1% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 26.1B | ↑ 15.89% |
Net Income | 3.4B | ↓ 30.55% |
Net Profit Margin | 13.15% | ↓ 8.8% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 42.5B | ↑ 62.62% |
Net Income | -9.0B | ↓ 361.56% |
Net Profit Margin | -21.16% | ↓ 34.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 46.4B | ↑ 9.09% |
Net Income | 7.0B | ↓ 177.75% |
Net Profit Margin | 15.08% | ↑ 36.24% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 46.2B | ↓ 0.49% |
Net Income | 6.3B | ↓ 9.54% |
Net Profit Margin | 13.71% | ↓ 1.37% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 45.0B | ↓ 2.5% |
Net Income | 8.0B | ↑ 26.84% |
Net Profit Margin | 17.83% | ↑ 4.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.4B | ↑ 1.68% |
Net Income | 2.0B | ↑ 25.9% |
Net Profit Margin | 17.73% | ↑ 3.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.3B | ↓ 0.6% |
Net Income | 2.3B | ↑ 11.87% |
Net Profit Margin | 19.95% | ↑ 2.22% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.2B | ↓ 0.98% |
Net Income | 2.1B | ↓ 8.36% |
Net Profit Margin | 18.47% | ↓ 1.48% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.0B | ↓ 2.32% |
Net Income | 1.9B | ↓ 6.99% |
Net Profit Margin | 17.58% | ↓ 0.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.5B | ↑ 4.66% |
Net Income | 1.8B | ↓ 8.61% |
Net Profit Margin | 15.35% | ↓ 2.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 11.9B | ↑ 3.38% |
Net Income | -11.9B | ↓ 775.99% |
Net Profit Margin | -100.39% | ↓ 115.74% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 10.7B | ↓ 68.23% |
Total Liabilities | 7.3B | ↓ 66.14% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 129.9B | ↑ 1119.1% |
Total Liabilities | 78.2B | ↑ 964.72% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 118.5B | ↓ 8.82% |
Total Liabilities | 80.6B | ↑ 3.01% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 109.3B | ↓ 7.74% |
Total Liabilities | 73.3B | ↓ 9.05% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 96.8B | ↓ 11.43% |
Total Liabilities | 65.7B | ↓ 10.38% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 95.2B | ↓ 1.72% |
Total Liabilities | 65.7B | ↓ 0.04% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 96.8B | ↓ 1.4% |
Total Liabilities | 65.7B | ↑ 0.37% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 94.3B | ↓ 2.62% |
Total Liabilities | 62.4B | ↓ 5.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 93.5B | ↓ 0.84% |
Total Liabilities | 61.5B | ↓ 1.5% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 91.3B | ↓ 2.38% |
Total Liabilities | 62.2B | ↑ 1.21% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 95.2B | ↑ 4.27% |
Total Liabilities | 65.7B | ↑ 5.58% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 99.0B | ↑ 4.07% |
Total Liabilities | 82.5B | ↑ 25.59% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.9B | ↑ 12.61% |
Investing Cash Flow | -874.0M | ↑ 1224.24% |
Financing Cash Flow | -3.5B | ↓ 13.29% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.1B | ↑ 35.81% |
Investing Cash Flow | -9.8B | ↑ 1017.85% |
Financing Cash Flow | 7.6B | ↓ 315.59% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.1B | ↑ 74.19% |
Investing Cash Flow | -10.9B | ↑ 11.15% |
Financing Cash Flow | -1.2B | ↓ 115.1% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 16.2B | ↑ 15.34% |
Investing Cash Flow | -538.0M | ↓ 95.05% |
Financing Cash Flow | -16.2B | ↑ 1309.56% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.1B | ↓ 19.38% |
Investing Cash Flow | -1.1B | ↑ 97.4% |
Financing Cash Flow | -17.0B | ↑ 4.55% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.9B | ↑ 6.08% |
Investing Cash Flow | -2.3B | ↑ 116.1% |
Financing Cash Flow | -9.4B | ↓ 44.49% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↓ 10.33% |
Investing Cash Flow | 1.2B | ↓ 158.29% |
Financing Cash Flow | -3.2B | ↓ 28.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.0B | ↓ 10.16% |
Investing Cash Flow | -210.0M | ↓ 117.31% |
Financing Cash Flow | -3.1B | ↓ 6.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↓ 36.46% |
Investing Cash Flow | -329.0M | ↑ 56.67% |
Financing Cash Flow | -2.2B | ↓ 28.75% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.8B | ↑ 151.78% |
Investing Cash Flow | -410.0M | ↑ 24.62% |
Financing Cash Flow | -5.2B | ↑ 137.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.3B | ↓ 10.5% |
Investing Cash Flow | -1.3B | ↑ 228.29% |
Financing Cash Flow | 967.0M | ↓ 118.74% |
Sell
Neutral
Buy
Bristol-myers Squibb Co. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Bristol-myers Squibb Co. | -10.01% | -9.96% | -33.13% | -32.83% | -4.92% |
Eli Lilly And Company | 6.02% | 28.85% | 74.06% | 291.84% | 562.48% |
Johnson & Johnson | 4.55% | 3.16% | -2.69% | -9.08% | 11.72% |
Merck & Co. Inc. | 4.3% | 27.77% | 13.59% | 65.31% | 66.32% |
Abbvie Inc | 0.01% | 20.32% | 14.69% | 43.65% | 108.49% |
Amgen Inc. | 16.19% | 17.76% | 39.86% | 25.68% | 85.56% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Bristol-myers Squibb Co. | 12.66 | NA | 2.24 | 0.56 | -0.25 | 0.05 | 0.05 | 8.14 |
Eli Lilly And Company | 113.57 | 113.57 | 1.43 | 13.79 | 0.51 | 0.13 | 0.01 | 14.23 |
Johnson & Johnson | 22.92 | 22.92 | 0.89 | 9.85 | 0.24 | 0.08 | 0.03 | 29.09 |
Merck & Co. Inc. | 145.42 | 145.42 | 0.1 | 8.0 | 0.05 | 0.1 | 0.02 | 15.94 |
Abbvie Inc | 49.06 | 49.06 | 0.45 | 11.25 | 0.56 | 0.08 | 0.04 | 4.54 |
Amgen Inc. | 45.02 | 45.02 | 2.39 | 19.44 | 0.73 | 0.05 | 0.03 | 9.36 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Bristol-myers Squibb Co. | Buy | $89.3B | -4.92% | 12.66 | -13.5% |
Eli Lilly And Company | Buy | $732.9B | 562.48% | 113.57 | 17.08% |
Johnson & Johnson | Hold | $371.3B | 11.72% | 22.92 | 44.92% |
Merck & Co. Inc. | Buy | $331.5B | 66.32% | 145.42 | 3.76% |
Abbvie Inc | Buy | $290.2B | 108.49% | 49.06 | 11.02% |
Amgen Inc. | Buy | $168.8B | 85.56% | 45.02 | 12.74% |
Vanguard Group Inc
BlackRock Inc
JPMorgan Chase & Co
State Street Corporation
Capital Research & Mgmt Co - Division 3
FMR Inc
In the quarter ending March,2024. Bristol-myers Squibb Co. has declared dividend of $0.6
Read MoreThe Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Organization | Bristol-myers Squibb Co. |
Employees | 34100 |
CEO | Dr. Christopher S. Boerner Ph.D. |
Industry | Health Technology |
Ppg Industries Inc.
$44.03
-0.18%
Microsectors Energy 3x Inverse Leveraged Notes Due January 29 2043
$44.03
-0.18%
Core Msci Total Intl Stk Ishares Etf
$44.03
-0.18%
Wec Energy Group, Inc.
$44.03
-0.18%
Paychex, Inc.
$44.03
-0.18%
Celanese Corporation
$44.03
-0.18%
Restaurant Brands International
$44.03
-0.18%
Rio Tinto Plc
$44.03
-0.18%
Thomson Reuters Corp.
$44.03
-0.18%